Tuesday, November 17, 2009

Life sciences software maker CambridgeSoft takes in more funds

By Mass High Tech staff

Video Gallery

Funding drugs for rare diseases

MHT's Julie Donnelly: Life science startups finding investments

MHT's Galen Moore: Hiring trends and opportunities

Related News

Charles River revenue hit by downturn [February 9, 2010]

Nyer Medical delisting paves way for dissolution [February 9, 2010]

Cosmetic laser firm Cynosure plans cost cuts amid sales drop [February 9, 2010]

Biogen's MS drug drives profits up in 2009 [February 9, 2010]

Nuance sees first quarter revenue gain [February 9, 2010]

CambridgeSoft Corp., a provider of life sciences software, has announced that it has closed a private equity investment from Health Evolution Partners and return backer Goldman Sachs.

The Cambridge-based firm did not disclose the amount of the recent funding, but to date, it has pulled in more than $26 million from Goldman Sachs and Edison Venture Funds.

The company develops and markets software aimed at improving productivity for the pharmaceutical, biotech, chemical and scientific research sectors. It develops its Chem & Bio Office programs in cloud computing, entreprise, workgroup and desktop versions.

In July, CambridgeSoft noted a $21 million private equity investment from Goldman Sachs & Co. in a deal that brought in Goldman Sachs vice president Raheel Zia to join CambridgeSoft’s board of directors.